Treatment
strategies mostly based on chemoradiotherapy are not efficient
for a number of cancer patients. Moreover, targeted therapy has been shown
to confer benefits, in some cancer types, for only a subset of patients.
Therefore, there
is a consensus among scientists and the medical community that the molecular
information of a particular tumor is necessary to support clinical decisions
even if considering the limited list of drugs available.
Despite the
advances in the development of targeted and immunotherapies, improvement of
response also rely on interpretation of tumor profile.
No comments:
Post a Comment